Metrics as of 10/13/2026, 06:33 PM (Berlin time), refresh in progress.
TriSalus Life Sciences Stock
TriSalus Life Sciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Mary T. Szela
- Employees
- 102
- Market cap
- $249 M
- IPO
- 08/02/2021
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic…
TriSalus Life Sciences stock: price history
1D
-2.9%
1W
-5.9%
1M
-13.9%
6M
-8.6%
YTD
-42.4%
1Y
-12.4%
2Y
-5.2%
5Y
-59.4%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~67% stronger price swings than usual
Ask the agents about TriSalus Life Sciences
Analyst assessment of TriSalus Life Sciences
PRICE TARGET LOW
US$8.00
CONSENSUS
US$11.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 23/09/2026
TriSalus Life Sciences stock metrics
P/E
-3.11
P/B
35.96
EV/EBITDA
-10.93
RETURN ON EQUITY
-140.3%
NET MARGIN
-80.5%
DEBT/EQUITY
5.26
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
62.0%
FLOAT SHARES
38,159,873
AVG. DAILY VOLUME (30D)
371,148
Insider transactions (SEC)
Szela Mary T
Cox Bryan F.
Marshak Richard
Stevens Jennifer
Patience David
Institutional holders
Comparable stocks
Frequently asked questions about TriSalus Life Sciences stock
What does TriSalus Life Sciences do?
TriSalus Life Sciences, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Mary T. Szela, the company employs around 102 people.
The IPO was on 08/02/2021; the stock trades on NASDAQ under the ticker TLSI.
What do analysts say about TriSalus Life Sciences stock?
4 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$11.00, ranging from US$8.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does TriSalus Life Sciences report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 67% stronger than usual.
Does TriSalus Life Sciences pay a dividend?
No, TriSalus Life Sciences currently does not pay a dividend.
Which stocks are comparable to TriSalus Life Sciences?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get TriSalus Life Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess TriSalus Life Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.